VIELA BIO, INC. Research and Development Expense (Excluding Acquired in Process Cost)
VIELA BIO, INC. reported Research and Development Expense (Excluding Acquired in Process Cost) of $103.30 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2021-03-01
- VIELA BIO, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2020-12-31 was $25.17M, a 22.62% decline year-over-year.
- VIELA BIO, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2020-09-30 was $25.89M, a 33.10% decline year-over-year.
- VIELA BIO, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2020-06-30 was $25.41M, a 51.16% increase year-over-year.
- VIELA BIO, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2020-03-31 was $26.83M, a 61.47% increase year-over-year.
- VIELA BIO, INC. research and development expense (excluding acquired in process cost) for fiscal 2020 was $103.30M, a 1.28% decline from fiscal 2019.
- VIELA BIO, INC. research and development expense (excluding acquired in process cost) for fiscal 2019 was $104.64M, a 146.71% increase from fiscal 2018.
- VIELA BIO, INC. research and development expense (excluding acquired in process cost) for fiscal 2018 was $42.41M.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $25.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $51.06M derived: sum of 2 quarters · filed 2021-03-01 | $76.47M derived: sum of 3 quarters · filed 2021-03-01 | $103.30M 10-K · filed 2021-03-01 |
| 2020-09-30 | $25.89M 10-Q · filed 2020-11-10 | $51.30M derived: sum of 2 quarters · filed 2020-11-10 | $78.13M 10-Q · filed 2020-11-10 | $110.66M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-06-30 | $25.41M 10-Q · filed 2020-08-12 | $52.24M 10-Q · filed 2020-08-12 | $84.77M derived: sum of 3 quarters · filed 2021-03-01 | $123.47M derived: sum of 4 quarters · filed 2021-03-01 |
| 2020-03-31 | $26.83M 10-Q · filed 2020-05-13 | $59.36M derived: sum of 2 quarters · filed 2021-03-01 | $98.06M derived: sum of 3 quarters · filed 2021-03-01 | $114.87M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-12-31 | $32.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $71.23M derived: sum of 2 quarters · filed 2021-03-01 | $88.04M derived: sum of 3 quarters · filed 2021-03-01 | $104.64M 10-K · filed 2021-03-01 |
| 2019-09-30 | $38.70M 10-Q · filed 2020-11-10 | $55.51M derived: sum of 2 quarters · filed 2020-11-10 | $72.11M 10-Q · filed 2020-11-10 | $85.65M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $16.81M 10-Q · filed 2020-08-12 | $33.43M 10-Q · filed 2020-08-12 | $46.95M derived: sum of 3 quarters · filed 2021-03-01 | $60.88M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $16.61M 10-Q · filed 2020-05-13 | $30.14M derived: sum of 2 quarters · filed 2021-03-01 | $44.06M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $27.45M derived: sum of 2 quarters · filed 2021-03-01 | $42.41M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $13.93M 10-Q · filed 2019-11-14 | $28.89M 10-Q · filed 2019-11-14 |